Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
EMERGEX VACCINES LTD logo — A UK biotechnology company developing T cell-priming immune...

EMERGEX VACCINES LTD

A UK biotechnology company developing T cell-priming immune set-point candidates against infectious diseases.

Founded 2016 United Kingdom United Kingdom 1 employees Grant Total: $12.47M Biopharma, Biotechnology +1

General Information

Company Name EMERGEX VACCINES LTD
Founded Year 2016
Location United Kingdom United Kingdom
Employees 1
Industries Biopharma, Biotechnology, Health Care
Funding Stage Grant
Social

BounceWatch is an independent company data service, not affiliated with EMERGEX VACCINES LTD. To contact EMERGEX VACCINES LTD, visit emergexvaccines.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does EMERGEX VACCINES LTD compare?

A PDF of EMERGEX VACCINES LTD and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting EMERGEX VACCINES LTD soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About EMERGEX VACCINES LTD

Emergex Vaccines is a pioneering UK biotechnology company that focuses on developing T cell-priming immune set-point candidates to combat infectious diseases. Founded in 2016, the company has its headquarters in the United Kingdom and an operating subsidiary in Pennsylvania, USA. Emergex's innovative approach involves utilizing synthetic T cell-priming immune set-point vaccine candidates to harness the body's natural CD8+ T cell immune response. The company's proprietary pipeline is designed to address a range of urgent health threats, including infectious diseases caused by viruses such as Betacoronavirus, Dengue Fever, and Universal Influenza A, as well as intra-cellular bacteria. Emergex has already completed two Phase I clinical trials for products targeting Dengue and Betacoronavirus disease, with other programs in development for Universal Influenza, Zika, Chikungunya, Smallpox/Monkeypox, Hand/Foot/Mouth Disease, a booster for Yellow Fever, and Francisella tularensis. The company's technology combines an empirically determined library of pathogen-derived protein fragments expressed on the surface of pathogen-infected cells with a self-assembling, ultrasmall carbohydrate-passivated nanocluster carrier system. This approach aims to deliver synthetic peptides to the skin-resident immune system to elicit a robust T cell response. In terms of funding, Emergex received a £490.53K grant investment from the Department of Health and Social Care (DHSC) on February 22, 2022. With its focus on leveraging T cell immunity to combat infectious diseases, Emergex Vaccines stands at the forefront of biopharma and biotechnology industries, offering promising solutions for global health challenges.

Business keywords: T Cell-Priming Vaccines, Infectious Diseases, Clinical-Stage Biotechnology, Immunotherapy, Vaccine Development, Pandemic Prevention, Pathogen-Targeted Immunotherapy, Nanotechnology in Vaccines, Global Health, Immunoproteomics, Clinical Trials, Public Health, Disease Prevention, Low-Resource Environments

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Grant £490.53K 1
Department of Health and Social Care (DHSC)
22 Feb 2022
Series A $11.00M 1
Vickers Venture Partners
Vickers Venture Partners
09 Jan 2020
Grant £979.32K 1
Innovate UK
Innovate UK
14 May 2018
Seed Round Undisclosed 1
Trend Investment Group
27 Jul 2017

EMERGEX VACCINES LTD Alternatives & Competitors

View All Alternatives
EMERGEX VACCINES LTD vs
FLUGEN, INC.
FLUGEN, INC.

Transforming vaccine efficacy in respiratory disease.

Grant
6 employees
Biotechnology, Health Care
EMERGEX VACCINES LTD vs
X-Vax Technology
X-Vax Technology

Pioneering the future of vaccines to conquer mucosal infections and protect millions globally.

Series A
Biotechnology, Health Care
EMERGEX VACCINES LTD vs
Curevo Vaccine
Curevo Vaccine United States

A clinical-stage biotech company developing amezosvatein, a vaccine for shingles and chickenpox.

Acquired
44 employees
Biopharma, Biotechnology
Compare EMERGEX VACCINES LTD vs Curevo Vaccine
Also compare with: EMERGEX VACCINES LTD vs Emmes Emmes EMERGEX VACCINES LTD vs Valneva Valneva View all alternatives

FAQ About EMERGEX VACCINES LTD

A UK biotechnology company developing T cell-priming immune set-point candidates against infectious diseases.
EMERGEX VACCINES LTD was founded in 2016.
EMERGEX VACCINES LTD is headquartered in United Kingdom.
EMERGEX VACCINES LTD operates in Biopharma, Biotechnology and Health Care. Its work centres on T Cell-Priming Vaccines, Infectious Diseases, Clinical-Stage Biotechnology and Immunotherapy.
EMERGEX VACCINES LTD has approximately 1 employees.
EMERGEX VACCINES LTD has completed 4 funding rounds, raising a total of $12.47M. The latest funding stage is Grant.
Top alternatives and competitors to EMERGEX VACCINES LTD include FLUGEN, INC., X-Vax Technology, Curevo Vaccine, BioVaxys Technology Corp., Emmes. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
EMERGEX VACCINES LTD and FLUGEN, INC. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for EMERGEX VACCINES LTD, https://bouncewatch.com/company/emergex-vaccines, updated 24 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout